Englander Institute for Precision Medicine

Publications

Found 805 results
Author Title Type [ Year(Asc)]
2020
Kaner J, Desai P, Mencia-Trinchant N, Guzman ML, Roboz GJ, Hassane DC.  2020.  Clonal Hematopoiesis and Premalignant Diseases.. Cold Spring Harb Perspect Med. 10(4)
Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, Tagawa ST, Nanus DM, Molina AM, Beltran H et al..  2020.  Common germline-somatic variant interactions in advanced urothelial cancer.. Nat Commun. 11(1):6195.
Bhinder B, Elemento O.  2020.  Computational methods in tumor immunology.. Methods Enzymol. 636:209-259.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez ABuqué, Chan TA, Coukos G, Demaria S, Deutsch E et al..  2020.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.. J Immunother Cancer. 8(1)
Pilones KA, Hensler M, Daviaud C, Kraynak J, Fucikova J, Galluzzi L, Demaria S, Formenti SC.  2020.  Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.. Oncoimmunology. 9(1):1830524.
Trieu T, Martinez-Fundichely A, Khurana E.  2020.  DeepMILO: a deep learning approach to predict the impact of non-coding sequence variants on 3D chromatin structure.. Genome Biol. 21(1):79.
Marderstein AR, Uppal M, Verma A, Bhinder B, Tayyebi Z, Mezey J, Clark AG, Elemento O.  2020.  Demographic and genetic factors influence the abundance of infiltrating immune cells in human tissues.. Nat Commun. 11(1):2213.
Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L.  2020.  Detection of immunogenic cell death and its relevance for cancer therapy.. Cell Death Dis. 11(11):1013.
Hadi K, Yao X, Behr JM, Deshpande A, Xanthopoulakis C, Tian H, Kudman S, Rosiene J, Darmofal M, DeRose J et al..  2020.  Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs.. Cell. 183(1):197-210.e32.
Rescigno P, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin AG, Schmid S et al..  2020.  Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.. Eur Urol Oncol. 3(2):176-182.
Vlachostergios PJ, Faltas BM, Carlo MI, Nassar AH, Alaiwi SAbou, Sonpavde G.  2020.  The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing.. Cancer Treat Res Commun. 23:100165.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP et al..  2020.  Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.. N Engl J Med. 382(23):2197-2206.
Sfakianos JP, Daza J, Hu Y, Anastos H, Bryant G, Bareja R, Badani KK, Galsky MD, Elemento O, Faltas BM et al..  2020.  Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers.. Nat Commun. 11(1):2540.
Nauseef JT, Villamar DM, Lebenthal J, Vlachostergios PJ, Tagawa ST.  2020.  An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.. Expert Opin Pharmacother. 21(8):863-870.
Pisapia DJ, Ohara K, Bareja R, Wilkes DC, Hissong E, Croyle JA, Kim J-H, Saab J, MacDonald TY, Beg S et al..  2020.  Fusions involving BCOR and CREBBP are rare events in infiltrating glioma.. Acta Neuropathol Commun. 8(1):80.
Elemento O.  2020.  The future of precision medicine: towards a more predictive personalized medicine.. Emerg Top Life Sci. 4(2):175-177.
Punjani N, Kang C, Lamb DJ.  2020.  Genetic implications of male-reproductive-health-associated comorbidities.. Turk J Urol.
Trapani D, Curigliano G, Alexandru E, Sternberg CN.  2020.  The global landscape of drug development for kidney cancer.. Cancer Treat Rev. 89:102061.
Davis M, Martini R, Newman L, Elemento O, White J, Verma A, Datta I, Adrianto I, Chen Y, Gardner K et al..  2020.  Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations.. Cancers (Basel). 12(5)
Claps M, Mennitto A, Guadalupi V, Sepe P, Stellato M, Zattarin E, Gillessen SSilke, Sternberg CN, Berruti A, De Braud FGuglielmo et al..  2020.  Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes.. Cancer Treat Rev. 88:102057.
Yamazaki T, Vanpouille-Box C, Demaria S, Galluzzi L.  2020.  Immunogenic Cell Death Driven by Radiation-Impact on the Tumor Microenvironment.. Cancer Treat Res. 180:281-296.
Galluzzi L, Petroni G, Kroemer G.  2020.  Immunogenicity of cell death driven by immune effectors.. J Immunother Cancer. 8(1)
Rodriguez-Ruiz MEsperanza, Vitale I, Harrington KJ, Melero I, Galluzzi L.  2020.  Immunological impact of cell death signaling driven by radiation on the tumor microenvironment.. Nat Immunol. 21(2):120-134.
Petroni G, Formenti SC, Chen-Kiang S, Galluzzi L.  2020.  Immunomodulation by anticancer cell cycle inhibitors.. Nat Rev Immunol. 20(11):669-679.
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):3819.